NasdaqGS:PHVSPharmaceuticals
How Investors May Respond To Pharvaris (PHVS) Narrower Losses And Phase 3 AAE-C1INH Trial Validation
In August 2026, Pharvaris reported second-quarter and first-half results showing a net loss of €47.84 million and €87.04 million, respectively, alongside narrower basic loss per share compared with the prior year.
A few days earlier, Pharvaris had highlighted publication of the first in-depth qualitative study in AAE-C1INH, which validates key patient-reported outcome measures and directly underpins endpoint selection in its Phase 3 CREAATE trial for this ultra-rare condition with no...